Mechanistically, IL6 and HH/GLI signaling integration occur at the level of cis-regulatory sequences by co-binding of GLI and STAT3 to common HH-IL6 target gene promoters and HH-IL6 pathway combinatorial blockade could efficiently arrest cancer growth in BCC patients [253]. Here, IL6 is linked to skin basal cell carcinoma.